Stockholders’ Equity (Details) - Schedule of Stock-Based Compensation Expense for Stock Options - Employee Stock [Member] - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
|
| Stockholders’ Equity (Details) - Schedule of Stock-Based Compensation Expense for Stock Options [Line Items] | ||||
| General and administrative | $ 88,271 | $ 124,984 | $ 207,470 | $ 205,464 |
| Sales and marketing | 128,840 | 126,564 | 258,587 | 262,547 |
| Research and development | 78,311 | 279,868 | 131,602 | 396,047 |
| Cost of goods sold | 16,330 | 19,022 | ||
| Total stock-based expense related to options | $ 311,752 | $ 531,416 | $ 616,681 | $ 864,058 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of selling and marketing expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|